<div id="readability-page-1"><div>                     <p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/solid-biosciences-inc-logo-1200x675.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1200" height="675" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/solid-biosciences-inc-logo-1200x675.jpg"/>Solid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) CEO Alexander Cumbo sold 48,913 shares of the firm's stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $6.44, for a total transaction of $314,999.72. Following the completion of the sale, the chief executive officer directly owned 222,018 shares in the company, valued at approximately $1,429,795.92. This trade represents a 18.05% decrease in their position. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink.</p><ul><li>Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside</li></ul><p>Alexander Cumbo also recently made the following trade(s): </p><ul><li>On Monday, February 2nd, Alexander Cumbo sold 80,258 shares of Solid Biosciences stock. The stock was sold at an average price of $6.44, for a total transaction of $516,861.52. </li><li>On Monday, February 2nd, Alexander Cumbo sold 80,258 shares of Solid Biosciences stock. The stock was sold at an average price of $6.44, for a total transaction of $516,861.52. </li><li>On Wednesday, December 3rd, Alexander Cumbo sold 10,808 shares of Solid Biosciences stock. The shares were sold at an average price of $5.11, for a total value of $55,228.88. </li></ul><h2>Solid Biosciences Stock Performance</h2><hr/><hr/><p>NASDAQ:SLDB opened at $6.52 on Friday. Solid Biosciences Inc. has a 1 year low of $2.41 and a 1 year high of $7.37. The stock has a market cap of $507.97 million, a P/E ratio of -2.62 and a beta of 2.67. The stock has a 50-day simple moving average of $5.84 and a 200-day simple moving average of $5.72. </p><h2>Hedge Funds Weigh In On Solid Biosciences</h2><ul><li>Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences</li></ul><p>Hedge funds and other institutional investors have recently made changes to their positions in the stock. Vestal Point Capital LP increased its position in  Solid Biosciences by 97.7% in the 3rd quarter. Vestal Point Capital LP now owns 2,975,000 shares of the company's stock valued at $18,356,000 after acquiring an additional 1,470,000 shares during the period.  Nantahala Capital Management LLC lifted its position in  Solid Biosciences by 505.4% during the 2nd quarter. Nantahala Capital Management LLC now owns 1,703,336 shares of the company's stock worth $8,295,000 after acquiring an additional 1,421,968 shares during the period.  Geode Capital Management LLC grew its stake in shares of  Solid Biosciences by 184.5% in the 2nd quarter. Geode Capital Management LLC now owns 1,510,153 shares of the company's stock valued at $7,356,000 after purchasing an additional 979,294 shares during the last quarter.  Bank of America Corp DE increased its holdings in shares of  Solid Biosciences by 2,150.4% in the second quarter. Bank of America Corp DE now owns 824,600 shares of the company's stock valued at $4,016,000 after purchasing an additional 787,957 shares during the period.  Finally, Woodline Partners LP acquired a new position in shares of  Solid Biosciences in the first quarter valued at approximately $2,338,000. Hedge funds and other institutional investors own  81.46% of the company's stock. </p><h2>Trending Headlines about Solid Biosciences</h2><p>Here are the key news stories impacting Solid Biosciences this week:</p><ul>   <li><span>Positive Sentiment: </span>Company will present at the Guggenheim Emerging Outlook: Biotech Summit (CEO Bo Cumbo presenting Feb 12) — this gives Solid (SLDB) direct exposure to institutional investors and can support a rally if management provides encouraging clinical, regulatory, or financing updates. <i></i><span>Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026</span></li>    <li><span>Neutral Sentiment: </span>Trading context: SLDB is trading above recent moving averages with volume notably above its average — this suggests heightened interest but does not by itself indicate direction until drivers (presentation vs. insider sales) dominate.</li>    <li><span>Negative Sentiment: </span>CEO Alexander (Alex) Cumbo sold 48,913 shares at an average $6.44 (≈$315k); his holding fell ~18.1% — a large CEO sale can be read negatively by investors even if for personal reasons. <i></i><span>CEO Sale SEC Filing</span></li>    <li><span>Negative Sentiment: </span>CFO Kevin Tan sold 14,783 shares at $6.44 (~$95k); his position fell ~13.6% — another senior officer reduction that may weigh on sentiment. <i></i><span>CFO Sale SEC Filing</span></li>    <li><span>Negative Sentiment: </span>COO David T. Howton sold 18,894 shares at $6.44 (~$122k); ownership declined ~16.2%. <i></i><span>COO Sale SEC Filing</span></li>    <li><span>Negative Sentiment: </span>CTO Paul Herzich sold 10,905 shares at $6.44 (~$70k); holding fell ~13.6%. <i></i><span>CTO Sale SEC Filing</span></li>    <li><span>Negative Sentiment: </span>Other insiders — director Ilan Ganot (7,205 shares), insider Jessie Hanrahan (12,348 shares), and Gabriel Brooks (12,616 shares) — each sold at $6.44, reducing holdings by double-digit percentages; collectively these sales increase supply pressure and raise investor questions about insider confidence. <i></i><span>Director/Insider Sales SEC Filings</span></li> </ul><h2>Wall Street Analysts Forecast Growth</h2><ul><li>Can Solid Biosciences Challenge Sarepta in the DMD Market?</li></ul><p>SLDB has been the topic of a number of recent analyst reports. Wall Street Zen downgraded shares of Solid Biosciences from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Sunday, October 19th. Barclays  set a $9.00 price objective on shares of Solid Biosciences and gave the company an &#34;overweight&#34; rating in a research note on Tuesday, November 4th. Citigroup  reiterated a &#34;market outperform&#34; rating on shares of Solid Biosciences in a research report on Wednesday, December 17th. Chardan Capital  reissued a &#34;buy&#34; rating and issued a $15.00 target price on shares of Solid Biosciences in a report on Tuesday, November 4th. Finally, Needham &amp; Company LLC  restated a &#34;buy&#34; rating and set a $16.00 price target on shares of Solid Biosciences in a research note on Wednesday, January 14th. Ten equities research analysts have rated the stock with a Buy rating and one  has given a Sell rating to the company's stock. According to data from MarketBeat, the stock  has an average rating of &#34;Moderate Buy&#34; and an average price target of $14.70.</p><p><b>View Our Latest Stock Analysis on SLDB</b></p><h2>About Solid Biosciences</h2><p> (Get Free Report)</p><p>Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company's primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.  </p><p>Solid's lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Solid Biosciences</li><li>NEW LAW: Congress Approves Setup For Digital Dollar?</li><li>The day the gold market broke</li><li>What a Former CIA Agent Knows About the Coming Collapse</li><li>Your Bank Account Is No Longer Safe</li><li>New gold price target</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0xEQg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0xEQg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].</em></p>                     <div>                         <p>Insider Buying or Selling at Solid Biosciences?</p>                         <p>Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Solid Biosciences and related companies.</p>                                                                       </div>                                                               <div>                         <p>From Our Partners</p><div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20251013195604_pushtrumpnew-3.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20251013195604_pushtrumpnew-3.jpg"/></p><div><p>NEW LAW: Congress Approves Setup For Digital Dollar?</p><p>Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0  But according to Rep. Marjorie Taylor ...</p><p><span>Goldco Precious Metals</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNzY2OQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNzY2OQ"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/20260123155602_blobid1.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="699" height="392" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/20260123155602_blobid1.png"/></p><div><p>The day the gold market broke</p><p>On September 14th, 2023, something big happened that didn't make the news. The price gap between London gold a...</p><p><span>Behind the Markets</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNzM0Mw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNzM0Mw"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.advantagegold.com/wp-content/uploads/2025/05/4f3bc4e2-image-1_10zg0si000000000000028.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1276" height="1026" original-src="https://imageproxy.pbkrs.com/https://www.advantagegold.com/wp-content/uploads/2025/05/4f3bc4e2-image-1_10zg0si000000000000028.png"/></p><div><p>What a Former CIA Agent Knows About the Coming Collapse</p><p> This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...</p><p><span>Advantage Gold</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNzQzNg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNzQzNg"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://files.admin.agorafinancial.com/Background/AWNAnncongress.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="678" height="780" original-src="https://imageproxy.pbkrs.com/https://files.admin.agorafinancial.com/Background/AWNAnncongress.png"/></p><div><p>Trump Planning to Use Public Law 63-43: Prepare Now</p><p>A little-known U.S. law is back in focus as analysts examine how existing presidential authorities could influ...</p><p><span>Paradigm Press</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNzQ4Mg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNzQ4Mg"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_2060push_Banking-9.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_2060push_Banking-9.jpg"/></p><div><p>[No Brainer Gold Play]: “Show me a better investment.”</p><p>A Historic Gold Announcement Is About to Rock Wall Street?  For months, sharp-eyed analysts have watched the...</p><p><span>Golden Portfolio</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNzUyMw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNzUyMw"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://marketingassets.marketwise.com/prod/images/brownstoneresearch/et/2025/10_Oct/2510_BNF_Helium_3_Spad_6.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="500" height="500" original-src="https://imageproxy.pbkrs.com/https://marketingassets.marketwise.com/prod/images/brownstoneresearch/et/2025/10_Oct/2510_BNF_Helium_3_Spad_6.jpg"/></p><div><p>Forget AI, This Will Be the Next Big Tech Breakthrough</p><p>After picking Nvidia in 2016, before it jumped 27,000%...  Jeff Brown is back with what he believes will be ...</p><p><span>Brownstone Research</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNzQ3NQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNzQ3NQ"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://mqebooks.s3.amazonaws.com/retirement/retire-guide-2-dn.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="540" height="500" original-src="https://imageproxy.pbkrs.com/https://mqebooks.s3.amazonaws.com/retirement/retire-guide-2-dn.png"/></p><div><p>Trade this between 9:30 and 10:45 am EST</p><p>If you can be at your computer between 9 a.m. and 10:45 a.m. on most weekdays, I’ll show you a simple trading ...</p><p><span>Base Camp Trading</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNzUzMA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNzUzMA"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20251221095140_pushstock-2463798640.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20251221095140_pushstock-2463798640.jpg"/></p><div><p>This $15 Stock Could Go Down as the #1 Stock of 2026</p><p>Wall Street veteran reveals #1 investment trend of 2026 (not AI)  Will you potentially make money or lose mo...</p><p><span>Chaikin Analytics</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNzQ5NQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNzQ5NQ"/></p></div></div></div>                     </div>                 </div></div>

SLDB

IBBQ

SBIO

ARKG

<p>Solid Biosciences CEO Alexander Cumbo sold 48,913 shares of the company's stock for $314,999.72, reducing his ownership by 18.05%. Following the sale, he holds 222,018 shares valued at approximately $1.43 million. This transaction was disclosed to the SEC. Cumbo also sold additional shares earlier, raising concerns among investors about insider selling. The stock is currently trading at $6.52, with a market cap of $507.97 million and a P/E ratio of -2.62. Institutional investors hold 81.46% of the stock, indicating strong interest despite recent insider sales.</p>

Market Beat

VanEck Biotech ETF

iShares Biotechnology ETF

Solid Biosciences

Invesco Nasdaq Biotechnology ETF

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

Solid Biosciences (NASDAQ:SLDB) CEO Sells $314,999.72 in Stock